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Background: The reactivity of AαC, a tobacco 
smoke carcinogen, was investigated with DNA and 
albumin of human hepatocytes. 
 
Results:  Hepatocytes bioactivate AαC to 
metabolites which adduct to DNA and albumin. 
 
Conclusion: Cys34 and Met329 of serum albumin are 
targets for AαC electrophiles. 
 
Significance:  AαC forms macromolecular adducts 
and induces oxidative stress, which may be 
contributing factors to liver damage and cancer risk 
in smokers. 
 
 
 
ABSTRACT 
 
2-Amino-9H-pyrido[2-3-b]indole (AαC) is a 
carcinogenic heterocyclic aromatic amine (HAA) 
formed during the combustion of tobacco. AαC 
undergoes bioactivation to form electrophilic N-
oxidized metabolites that react with DNA to form 
adducts, which can lead to mutations. Many 
genotoxicants and toxic electrophiles react with 
human serum albumin (albumin); however, the 
chemistry of reactivity of AαC with proteins has 
not been studied. The genotoxic metabolites, 2-
hydroxyamino-9H-pyrido[2-3-b]indole (HONH-
AαC), 2-nitroso-9H-pyrido[2-3-b]indole (NO-
AαC), a N-acetoxy-9H-pyrido[2-3-b]indole (N-
acetoxy-AαC), and their [13C6]-AαC labelled 
homologues were reacted with albumin. Sites of 
adduction of AαC to albumin were identified, by 
data dependent scanning and targeted bottom-up 
proteomics approaches employing ion trap and 
Orbitrap MS.  AαC–albumin adducts were 
formed at Cys34, Tyr140 and Tyr150 residues, when 
albumin was reacted with HONH-AαC or NO-
AαC. Sulfenamide, sulfinamide, and sulfonamide 
adduct formation occurred at Cys34 (AαC-Cys34). 
N-Acetoxy-AαC also formed an adduct at Tyr332.  
Albumin-AαC adducts were characterized in 
human plasma treated with N-oxidized 
metabolites of AαC and human hepatocytes 
exposed to AαC. High levels of N-
(deoxyguanosin-8-yl)-AαC (dG-C8-AαC) DNA 
adducts were formed in hepatocytes. The Cys34 
was the sole amino acid of albumin to form 
adducts with AαC.  Albumin also served as an 
antioxidant and scavenged reactive oxygen 
species (ROS) generated by metabolites of AαC in 
hepatocytes:  there was a strong decrease in 
reduced Cys34 while the levels of Cys34sulfinic 
acid (Cys-SO2H), Cys34-sulfonic acid (Cys-SO3H) 
and Met329 sulfoxide were greatly increased. 
Cys34-adduction products and Cys-SO2H, Cys-
SO3H and Met329 sulfoxide may be potential 
biomarkers to assess exposure and oxidative 
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stress associated with AαC and other arylamine 
toxicants present in tobacco smoke. 
_______________________________________ 
 
Tobacco smoke is a major risk factor for 
lung cancer, but also cancer of the liver, bladder, and 
gastrointestinal tract (1-4). The combustion of 
tobacco produces many genotoxicants including 
polycyclic aromatic hydrocarbons, nitrosamines, 
aromatic amines, and heterocyclic aromatic amines 
(HAAs), which are potential human carcinogens (5). 
AαC was originally discovered as a mutagenic 
pyrolysis product of protein (6) and subsequently 
identified in cigarette smoke at levels ranging from  
60 - 250 ng/cigarette (7,8). These quantities are far 
greater than  those of the aromatic amines 4-
aminobipehnyl and 2-naphthylamine, which are  
implicated in the pathogenesis of bladder cancer in 
smokers  (1,9). Apart from the endocyclic nitrogen 
atoms, AαC  shares the same structure as 2-
aminofluorene, one of the most well studied 
aromatic amine carcinogens (10). Significant levels 
of AαC were detected in the urine of male smokers 
of the Shanghai cohort in China, providing evidence 
that tobacco smoke is a major source of AαC 
exposure (11). AαC is a liver carcinogen in mice, a 
transgene colon mutagen and an inducer of colonic 
aberrant crypt foci, an early biomarker of colon 
neoplasia (12-14).  Therefore, AαC could play a role 
in the incidence of liver or digestive tract cancers of 
smokers.  
AαC undergoes metabolic activation by N-
oxidation of the exocyclic amine group, by 
cytochrome P450 (P450) enzymes, to form 2-
hydroxyamino-9H-pyrido[2-3-b]indole (HONH-
AαC) (Fig.1) (15,16). HONH-AαC can undergo 
conjugation reactions with N-acetyltransferases or 
sulfotransferases, to form unstable esters. These 
metabolites undergo heterolytic cleavage to form the 
proposed short-lived nitrenium ion of AαC (Fig.1) 
(17), which reacts with DNA to form covalent 
adducts, leading to mutations (18).  The genotoxic 
potential of AαC has been shown in  human 
peripheral blood lymphocytes (19), Chinese hamster 
ovary cells (18),  and human hepatocytes (20), where 
high levels of AαC-DNA adducts are formed. 
However, long-term stable biomarkers of AαC must 
be developed for implementation in molecular 
epidemiology studies that seek to address a role for 
this chemical in human cancer risk.  
DNA adducts of AαC can be measured by 
sensitive liquid chromatography/mass spectrometry 
(LC/MS)-based methods (20). However, DNA from 
biopsy specimens is often unavailable, and restricts 
the use of this biomarker. The electrophilic N-
oxidized metabolites of AαC are also expected to 
react with proteins (21).  The biomonitoring of 
protein-carcinogen adducts is an alternative 
approach to assess exposure to hazardous chemicals.  
Stable carcinogen protein adducts do not undergo 
repair and are expected to follow the kinetics of the 
lifetime of the protein (22,23). The major proteins in 
blood are hemoglobin (Hb) with a life-span of 60 
days, and human serum albumin  with a half-life of 
21 days. The chemistry of reactivity of Hb and 
albumin with various genotoxicants and toxic 
electrophiles have been reported (24-26), and several 
protein-carcinogen adducts have been employed to 
assess human exposures (23,27,28).  
Our goal is to develop and implement 
protein-based biomarkers of AαC and other HAAs  
(29,30) in molecular epidemiological studies 
designed to assess the role of HAAs in human 
cancers. In this study, we have examined the 
reactivity of albumin with N-oxidized metabolites of 
AαC. Cys34, followed by Tyr140 and Tyr150 of 
albumin were major sites of adduction of AαC 
electrophiles. The Cys34 and Met329 residues of 
albumin also served as scavengers of reactive 
oxygen species (ROS) generated by metabolites of 
AαC, and the Cys34 sulfinic acid (Cys-SO2H), 
sulfonic acid (Cys-SO3H),  and Met329 sulfoxide 
were recovered in high yield from human 
hepatocytes treated with AαC.  
 
EXPERIMENTAL PROCEDURES 
Caution — AαC is a potential human carcinogen. 
AαC and its derivatives must be handled in a well-
ventilated fume hood with proper use of gloves and 
protective clothing. 
Chemicals and Materials— AαC was 
purchased from the Toronto Research Chemicals 
(Toronto, ON, Canada). [4b,5,6,7,8,8a-13C6]AαC 
was a gift from Dr. Daniel Doerge, National Center 
for Toxicological Research (Jefferson, AR). 
Albumin, trypsin, chymotrypsin, pronase E, 
prolidase, leucine amino peptidase, β-
mercaptoethanol (βME), iodoacetamide (IAM), 
dithiothreitol (DTT), acetic anhydride, and  Pd/C 
were obtained from Sigma-Aldrich Chemical Co. 
(St. Louis, MO).  LC-MS grade solvents were from 
Fisher Scientific (Pittsburg, PA). Tetrahydrofuran 
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(THF) was obtained from Alfa Aeser (Ward Hill, 
MA). Amicon Ultra Centrifugal Filters (10 kDa cut 
off) were purchased from Millipore (Billerica, MA). 
Pierce albumin depletion kit was purchased from 
Thermo Scientific (Rockford, IL). Human plasma 
was purchased from Bioreclamation LLC 
(Hicksville, NY).  
Synthesis of N-oxidized metabolites of 
AαC—2-Nitro-9H-pyrido[2,3-b]indole (NO2-AαC) 
and [13C6]-NO2-AαC were prepared by oxidation of 
AαC with dimethyldioxirane (17). HONH-AαC and 
HONH-[13C6]AαC were prepared by reduction of 
NO2-AαC in THF with hydrazine, using Pd/C as a 
catalyst (31). HONH-AαC was oxidized to 2-
nitroso-9H-pyrido[2,3-b]indole (NO-AαC) with a 
potassium ferricyanide (32). N-(Deoxyguanosin-8-
yl)-AαC (dG-C8-AαC) and the isotopically labeled 
internal standards [13C10]-dG-C8-AαC were 
synthesized as described (33).   
Modification of albumin and human plasma 
with N-oxidized metabolites of AαC— Mixed 
disulfides formed at Cys34 of commercial albumin 
(34) were reduced by treatment with βME (35). The 
reduced albumin was recovered in 100 mM 
potassium phosphate buffer (pH 7.4) employing 
Amicon Ultra centrifugal filters. The reduced 
albumin contained 0.98 mol Cys34/mol albumin upon 
βME treatment. An equimolar solution of HONH-
AαC and HNOH-[13C6]AαC or N-acetoxy-AαC and 
N-acetoxy-[13C6]AαC (15 nmol,  in 10 µL EtOH) or 
NO-AαC (30 nmol in 10 µL EtOH) was reacted with 
albumin (0.6 nmol, 40 µg) in 1 ml of 100 mM 
potassium phosphate buffer (pH 7.4) at 37 ºC for 18 
h.  N-Acetoxy-AαC and N-acetoxy-[13C6]AαC were 
prepared in situ by adding the HONH-AαC (15 
nmol) to the solution of albumin, immediately 
followed by the addition of  450 nmol of acetic 
anhydride (36),  and incubated at 37 ºC for 1 h. N-
Acetoxy-AαC and N-acetoxy-[13C6]AαC were 
prepared in situ by adding the HONH-AαC (15 
nmol) to the solution of albumin, immediately 
followed by the addition of  450 nmol of acetic 
anhydride (36),  and incubated at 37 ºC for 1 h. The 
unreacted AαC metabolites were removed by ethyl 
acetate extraction. Human plasma (5 µL, containing 
~200 µg of albumin, 3 nmol) was diluted with 1 ml 
PBS and reacted with N-oxidized AαC derivatives as 
described above. Albumin from plasma was purified 
affinity purification by Pierce albumin depletion kit. 
Other studies on AαC-albumin adduct formation 
were carried out using lower amounts of N-oxidized 
AαC (vide infra). 
Human hepatocyte cell culture— Human 
samples were obtained from the Centre de 
Ressources Biologiques (CRB)-Santé of Rennes 
(http://www.crbsante-rennes.com). The research 
protocol was conducted under French legal 
guidelines and approved by the local institutional 
ethics committee. Hepatocytes were isolated by a 
two-step collagenase perfusion, and the parenchymal 
cells were seeded at a density of ~ 3 x 106 viable 
cells /19.5 cm2 Petri dish in 3 mL of Williams’ 
medium with supplements as reported (20), except 
fetal calf serum was replaced with  human albumin 
pretreated with βME (1 g/L). After two days, the 
differentiated cells were incubated with AαC 
(20,33). 
Albumin and DNA adduct formation with 
AαC in Hepatocytes— Metabolism studies with AαC 
(0 or 50 µM  in DMSO, 0.01% v/v) were conducted 
for 24 h. A solution of 1:1 AαC and [13C6]AαC (50 
µM) was employed for characterization of AαC-
albumin adducts, whereas the DNA adduct studies 
employed AαC (50 µM).  The culture media 
containing albumin were removed after 24 h 
incubation and immediately stored at -80 ºC. The 
cells were washed with PBS and cell pellets were 
collected by centrifugation a 3500 g for 10 min at 4 
ºC. Cells were stored at -80 ºC until further use. Cell 
viability was determined by methylthiazol-
tetrazolium test and treatment with AαC did not 
decrease cell viability (37). The   media was 
extracted with 3 vol of ethyl acetate and then the 
albumin was recovered with >85% purity, by ethanol 
precipitation. For some analyses, the albumin (100 
µg, 1.5 nmol) was alkylated with a 100 molar excess 
IAM (150 nmol) at 37 ºC for 1 h. Excess of IAM 
was removed by Amicon Ultra centrifugal filters.  
Trypsin/chymotrypsin digestion— The 
digestion of AαC-modified albumin (10 µg) was 
carried out using trypsin and chymotrypsin at 
protease:protein ratio, respectively, at 1:50 (w/w) 
and 1:25 (w/w), in 100 µL 50 mM ammonium 
bicarbonate buffer (pH 8.5) containing CaCl2 (1 
mM) at 37 ºC for 16-18 h (35). 
  Pronase E/leucine aminopeptidase/proli-
dase digestion— albumin (10 µg, 150 pmol) was 
digested with pronase E, leucine aminopeptidase and 
prolidase at a protease to protein ratios, respectively, 
at 1:2 (w/w), 1:30 (w/w) and 1:8 (w/w), in 50 mM 
ammonium bicarbonate buffer (pH 8.5) containing 
MnCl2 (1 mM) at 37 ºC for 20 h  (23). The AαC-
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amino acid adducts were enriched by SPE (32).  
 UPLC-Mass Spectrometry Parameters for 
Peptide Analyses— Peptides were resolved with an 
Atlantis C18 nanoACQUITY column (0.3 mm x 150 
mm, 3 µm particle size, 100 Å) (Waters Corp., 
Milford, MA) using Solvent A (5% acetonitrile, 
94.99% water, 0.01% formic acid) and Solvent B 
(95% acetonitrile, 4.99% water, 0.01% formic acid) 
as mobile phases with Thermo Dionex Ultimate 
3000 Nano/Cap LC System connected to an Orbitrap 
Elite Mass spectrometer (Thermo Scientific, San 
Jose, CA) using an Advance CaptiveSpray source 
(Auburn, CA) in the positive ionization mode.   
 A 60 min gradient (99% A solvent to 60% B 
solvent for 45 min, 60 to 99% B solvent at 45-60 
min) and 25 min gradient (99% A solvent to 60% B 
solvent for 20 min and 60% to 90% B solvent for 
20-25 min) at 5 μL/min flow rate were used, 
respectively, for data dependent (DDA) and targeted 
data acquisition.  
The top five precursor ions for CID-MS/MS 
analysis with dynamic exclusion for 180 s with a 3 
repeats for 60 s repeat duration were selected for 
DDA. Mass-tag DDA (MS-tag DDA) was employed 
to trigger MS/MS on peptides and amino acid 
adducts displaying characteristic pattern of 1:1 
isotopic mixture of AαC and [13C6]-AαC (40). The 
partner intensity ratio of 85-100%; m/z difference of 
6 (singly charged), 3 (doubly charged), 2 (triply 
charged) species. A mass list of precursor ions 
(Table 1) for AαC-amino acid and AαC-peptide 
adducts identified from MS-tag DDA were used for 
targeted analysis.  
The tune parameters were: capillary tube 
temperature, 270 ºC; spray voltage, 2.5 kV; S-lens 
RF level, 68 (%); in-source fragmentation, 5 V; 
collision gas, Helium; normalized collision energy, 
35 eV; activation Q 0.3; HCD collision gas, Argon; 
HCD collision energy, 20 - 35. Full scan data were 
acquired over a mass range of 150-1800 m/z at a 
resolving power of 120,000 (at 400 m/z), whereas, 
MS/MS data acquisition was carried out with the 
iontrap or Orbitrap (resolving power 60,000) as mass 
analyzer with isolation widths 1.5, 2. An internal 
lock mass at m/z 371.1012 (polysiloxane) was 
employed while using the orbitrap mass analyzer.   
The tune parameters were optimized with 
LQQCPFEHVK and LQQCPF peptides (New 
England Peptide, Gardner MA). Mass spectral data 
were acquired with Xcalibur version 3.0.63 
software. 
Data analysis of AαC-albumin — The 
BumberDash platform (Version 1.4.115) with 
Myrimatch search algorithm (Version 2.1.138) with 
31 protein subset of  RefSeq human protein 
database, version 37.3, with their forward and 
reverse protein sequences were used to search for the 
AαC-peptide adducts (29,38). The dynamic 
modifications used in Myrimatch configuration file 
were: oxidation (+15.99 Da) on Met, Cys; 
deamidation (-17.03 Da) on N-terminal Gln; AαC 
and [13C6]-AαC (+181.06 and 187.11) on Cys, Lys, 
Tyr, Ser, Thr, Trp, His, Glu, Asp; SO-AαC and SO-
[13C6]-AαC (+197.06, +203.10) on Cys and SO2-
AαC and SO2-[13C6]-AαC (+213.05, +219.10); 
acetylation (+42.01) on Lys, Cys, Tyr, Arg. The 
search parameters used were: enzyme 
(trypsin/chymotrypsin), up to two missed cleavages, 
mass tolerances 1.25 m/z (precursor ions) and 0.5 
m/z (product ions). Each identified spectrum was 
filtered by IDPicker algorithm (Version 3.0.564) 
with a false discovery rate (FDR) (1%). The peptide 
sequence of identified AαC-peptide and AαC-
monoamino acid adducts was confirmed by 
manually sequencing.  
 DNA isolation and UPLC/MS3 measurement 
of AαC-DNA adducts— DNA was isolated by the 
phenol/chloroform method (20). DNA (5 µg) was 
spiked with the isotopically labeled internal standard 
([13C10]-dG-C8-AαC) at 1 adduct per 106 bases, 
followed by enzymatic digestion of DNA (39).  The 
UPLC /MS3 measurement of AαC-DNA adducts 
were performed using a NanoAcquity UPLC system 
(Waters Corp., New Milford, MA) coupled with 
LTQ VelosPro ion-trap mass spectrometer (Thermo 
Fisher, San Jose, CA) as described previously (42). 
The ions were monitored with the MS3 scan mode. 
For dG-C8-AαC, ions at m/z 449.1 (MS) > 333.1 
(MS2) > 209.2, 291.4, 316.4 (MS3) and for the 
internal standard, [13C10]-dG-C8-AαC, ions at m/z 
459.1 (MS) > 338.1 (MS2) > 210.2, 295.4, 321.5 
(MS3) were monitored (40).  
RESULTS 
The metabolic activation of AαC in hepatocytes, and 
reaction of  N-oxidized AαC metabolites with DNA 
and albumin, and the scavenging of ROS by albumin 
are summarized in Fig. 1.  
The UV spectra of AαC, HONH-AαC, and 
NO-AαC are displayed in Fig 2A. NO-AαC displays 
a redshift in its maximal absorbance compared to 
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AαC and HOHN-AαC. The product ion spectrum of 
AαC ([M+H]+ at m/z 184.1) displays fragment ions 
at m/z 167.0 and 157.1, atributed to the loss of NH3 
and HCN (Fig 2B) (9). The product ion spectrum of 
NO-AαC ([M+H]+ m/z 198.1) displays a sole ion at 
m/z 168.0 and assigned to  the loss of the NO group  
(Fig 2C). The product ion spectrum  of HONH-AαC  
([M+H]+ at m/z 200.1) displays prominent fragment 
ions at  at m/z 182.1 and 183.1, which  are  attributed 
to the losses of H2O and OH●,  and the  product ion 
at m/z 155.1 is attributed to a loss of H2O and HCN 
(Fig 2D). 
MS-tag DDA mapping of AαC-albumin 
peptides and AαC-amino acid adducts— The 
assignment of AαC-peptide adducts are based on 
CID and higher-energy collision dissociation (HCD) 
tandem MS. 
The chromatograms of the MS-tag DDA 
experiments of albumin modified with a 50-fold 
molar excess of  N-oxidize AαC and [13C6]AαC (1:1 
ratio) were filtered using  m/z values of the isotopic 
pair, i.e. for the radical cation  (AαC●+ at m/z 183.1, 
[13C6]AαC●+ at m/z 189.1) and protonated ions   
(AαC+  at m/z 184.1 and [13C6]AαC at m/z 190.1).  
(Fig. 3). Nine AαC-peptide adducts (P1-P9) were 
detected in the tryptic/chymotryptic digest. The 
assignments of the peptide adduct sequences and 
accurate mass measurements of the amino acid 
adducts, following digestion with pronase E, leucine 
aminopeptidase,  and prolidase, are listed in Table 1.  
Cys34, followed by Tyr140 and Tyr150 formed adducts 
with HONH-AαC; an additional adduct was formed 
at Tyr332 with N-acetoxy-AαC. The adduction of 
NO-AαC primarily occurred at Cys34, followed by 
much lower levels of adduct formation at Tyr150.  
MS characterization of adducts formed at 
Cys34 of albumin- The digestion of  AαC-modified 
albumin with trypsin/chymotrypsin produced 
peptides containing adducts at 31LQQC*PF36, 
32QQCPFEDHVK41 and 31LQQCPF EDHVK41. A 
total of six adducts with  different oxidation states of 
the sulfur atom were identified. The product ion 
spectra of several adducts peptides are described in 
detail below. LQQ*CPFEDHVK-AαC adducts— 
The single missed cleavage peptide containing the  
proposed sulfonamide adduct LQQ*C[SO2AαC]PF 
EDHVK (P2) (1555.7 Da), eluted at tR = 17.7 min 
and occurred as a tripley charged species [M+3H]3+ 
at m/z 519.6 (Fig. 4A). The 213 Da increase in mass 
over the non-modified peptide corresponds to the 
addition of AαC (182), and two oxygen atoms (32)  
minus  one proton (1) on the –SH moiety.  The 
product ion spectrum of m/z 519.6  displayed  a 
series of -b ions and -y ions confirming the sequence 
assignment.The shift in masses at the *b4 and (*y8)2+  
ions identify the site of adduction at the Cys34 
residue. The proposed sulfinamide adduct  
LQQ*C[SOAαC]PF EDHVK (P3) (1539.7 Da) at tR = 
17.8 min  occurred as a tripley charged species  
[M+3H]3+  at m/z 514.2, a mass 16 Da less than the 
sulfonamide adduct.  The product ion spectrum of  
m/z 514.2 contains minor fragment ions at m/z 183.1 
(AαC●+) and 184.1 (AαC+), with  a base peak at m/z 
679.9, corresponding to the sulfonium ion [M+2H-
AαC]2+  (Fig. 4B). The MS3 scan stage product ion 
spectrum of the proposed LQQ*C[SO]PFEDHVK 
sulfoxide ion at m/z  679.9 [M'] showed -b and -y 
ions series in MS3 scan stage product ion spectrum  
at m/z  679.9 [M'] supports LQQ*C[SO]PFEDHVK 
sulfoxide structure. Doubly charged product ion at 
m/z 648.9 attributed to the loss of CH2SO from the 
M′ ion and *b4-SO, *b5,*y8 and *y9 ions support the 
proposed structure (Fig. 4C). 
LQQ*CPF-AαC peptide adducts— Three 
additional S-N linked peptide adducts were 
identified. The product ion mass spectra of the  
doubly protonated ions are consistent with the AαC 
sulfonamide LQQ*C[SO2AαC]PF (P4) ([M+H]+ at m/z 
948.4, [M+2H]+ at m/z 474.7 tR 17.9 min) (Fig. 4D), 
AαC sulfinamide LQQ*C[SOAαC]PF (P7) ([M+H]+ at 
m/z 932.4, [M+2H]+ at m/z 466.7  tR 20.4 min) (Fig. 
4E-F),  and AαC sulfenamide LQQ*C[AαC]PF (P8) 
([M+H]+ at m/z 916.4, [M+2H]+ at m/z 458.7  tR 21.5 
min) (Fig. 4G).     
The doubly charged peptide precursor ion  
[M+2H]2+  of LQQ*C[AαC]PF (P8) [M+H]+  at  m/z 
458.7  is  a 181 Da increase in mass over the non-
modified protonated peptide (m/z 735.3). This 
increase in mass corresponds to the addition of AαC 
(182)  minus  one proton (1) from the –SH moiety. 
The increase in mass of the peptide is consistent 
with the proposed sulfenamide linkage. The product 
ion spectrum of [M+2H]+2 at m/z 458.7 (Fig. 4G) 
shows the -b ion   and -y ion series, where *b4, *y3-
*y5 ions provide evidence that adduction of AαC 
occurred at the sulfhydryl group of Cys34. The 
product ion at m/z 439.3 (*b4-AαC-SH) occurs via 
the cleavage of the C-S bond (41,42).  The 
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prominent base peak observed at m/z 184.1 is 
attributed to protonated AαC (Fig. 4G). It is 
noteworthy that most arysulfenamide adducts 
undergo hydrolysis during proteolytic digestion, 
which generally makes these adducts difficult to 
detect (30,43,44).  
MS characterization *Cys-AαC  adducts — 
The Cys sulfenamide and sulfinamide linked adducts 
of AαC underwent hydrolysis to produce AαC 
during proteolysis of albumin with pronase E, 
leucine aminopeptidase,  and prolidase. Two  peaks 
attributed to Cys-AαC adducts containing the S-
dioxide linkage were identified  (tR = 10.9 and 11.5 
min) (A1) in  the UPLC/MS chromatogram (Fig. 5A-
B). The  precursor ions [M+H]+  were observed at  
m/z 335.0806, a value which is within 0.6 ppm of the 
calculated m/z value of the proposed sulfonamide 
structure (Table 1).  The adducts were present in an 
approximate ratio of 4:6 in albumin modified with 
HONH-AαC,  and a 2:8 ratio when albumin was 
modified with N-acetoxy-AαC Fig. 5A-B). The 
adducts were formed at ~5 fold higher levels in 
albumin treated with N-acetoxy-AαC than albumin 
treated with HONH-AαC.   The earlier eluting 
isomer underwent CID to preferentially form a 
radical cation at m/z 183.0790 (AαC●+), whereas the 
second adduct favored the formation of the even 
electron ion at m/z 184.0867, the m/z of protonated 
ion of AαC+ (Fig. 5C-D,  Table 2).  Other notable 
product ions were detected for both adducts but with 
different relative abundances: m/z 230.0382 
([AαC+SO]+); m/z 254.0922 ([M+H-NH3-SO2]+); 
m/z 271.1189 ([M+H-SO2]+); and  m/z 318.0547 
([M+H-H2O(Fig. 5C-D,  Table 2).   
Arylsulfonamides are weak acids and the 
nitrogen anion of the sulfonamide linkage  can form 
several tautomeric forms with hindered rotation 
about the S=N bond  (45). However, the prominent 
differences in the product ion spectra combined with 
the inability to interconvert these Cys-AαC adducts 
at elevated temperature, suggest that the adducts are 
not conformational isomers.  
The nitrenium ion of HONH-AαC can 
undergo charge delocalization to form the carbenium 
ion resonance form with electron deficiency centered 
at the C-3 position of the AαC skeleton (Fig. 5E)  
(46). We propose that one isomeric Cys-AαC adduct 
contains an S-N linkage, and the second adduct 
contains a thioether linkage, formed between Cys34-
SH group and possibly the C-3 atom of AαC (46). 
The S-N sulfenamide (or sulfinamide) and thioether 
adducts undergoes oxidation, by ROS generated  by 
aerobic oxidation of N-oxidized AαC metabolites 
(Fig. 1)  or during proteolysis, to form the 
sulfonamide and sulfone linkages (Fig. 5E) (47). 
Both adducts undergo CID to form the proposed 
sulfonium ion  at m/z 230.0385 (Fig. 5F)).  These 
adducts were not chromatographically resolved in 
the tryptic/chymotryptic digests of albumin. Large 
scale syntheses and NMR studies are required to 
elucidate the respective structures of these AαC-
Cys-S-dioxide linked isomers.  The Cys34 of albumin 
was reported to react with N-acetyl-p-
benzoquinoneimine, the electrophilic metabolite of 
acetaminophen and formed two regioisomeric 
adducts (41).  
MS characterization of adducts formed at 
Tyr140,150,332 of albumin— Three adducts were formed 
between Tyr residues of albumin and AαC (Table 1).   
L*YEIAR peptide adduct—The product ion 
spectrum of the L*YEIAR (P5) adduct with a doubly 
charged peptide precursor ion [M+2H]2+ at m/z  
473.3 (tR = 14.1 min) displayed a series of -b ions  
and -y ions [identifies the sequence as 
139L*Y[AαC]EIAR144 with the site of adduction at 
Tyr140 (Fig. 6A).  The  ion at m/z 763.4 is proposed to 
arise by the loss of AαC as a radical cation at m/z 
183.1 [M+H−AαC●]+, followed by the neutral loss of 
quinone methide (106.1 Da) [M+H−AαC●–C7H6O]+ 
to form the ion at m/z 657.4 (Fig. 6B). The mass 
spectral data support the proposed structure as an O-
linked adduct formed between oxygen atom of Tyr 
and possibly the C-3  atom of the heterocyclic 
skeleton of AαC (46). Further support for the 
proposed O-linkage is provided by the lower region 
of the HCD mass spectrum: ions are observed at m/z 
183.0790 (m/z 183.0791, calculated) and m/z 
199.0745 (m/z 199.0741, calculated) and attributed 
to, respectively, [AαC●]+ and [AαC+O●]+ (Fig. 6A-
B).  We recently reported a similar mechanism of 
fragmentation of an O-linked adduct formed 
between tyrosine and the HAA 2-amino-1-methyl-6-
phenylmidazo[4,5-b]pyridine (PhIP) (32). 
MS characterization of an O-linked Tyr-AαC   
adduct— The proteolysis of albumin adducts with 
pronase E, leucine aminopeptidase, and prolidase 
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produced two Tyr linked adducts of AαC. A first set 
of Tyr-AαC and Tyr-[13C6]AαC adducts (A2) were 
observed at m/z 363.1449 (m/z 363.1451, calculated) 
and m/z 369.1629 (m/z 369.1631, calculated) were 
observed at tR 11.8 min. The product ion spectrum of  
the unlabelled Tyr-AαC adduct [M+H]+  at m/z 
363.1449 displayed fragment ions at m/z 346.1186, 
317.1395, and 302.1285 attributed, respectively, to 
the losses of NH3, H2CO2, and NH3 and CO2 (Fig. 
6C, Table 2).  The product ions at m/z 289.1210 
[M+H-C2H5NO2]+  and  288.1137 [M+H-C2H4NO2]+ 
are proposed to arise by cleavage of the Cα and Cβ 
bond of tyrosine. The fragment ion at m/z 183.0791 
is assigned to AαC●+, and the ion at m/z 198.0659 is 
tentatively assigned as the protonated ion of the 2-
imino-3-oxo derivative of AαC, with the loss of 
phenylalanine (165.0790 Da) as a neutral fragment. 
The ion at m/z 198.0659 provides evidence that 
adduct formation occurred between the 4-HO group 
of tyrosine and the AαC heterocyclic ring (Fig. 6D). 
F*YAPELL-AαC adducts— Two minor Tyr 
adducts of AαC with the peptide sequence 
149F*Y[AαC]APELL155 (P9A, P9B Fig. 3, Table 1) 
were identified at tR 14.5 and 15.8 min (Fig. 7A). 
The full scan spectra of both adducts displayed 
doubly charged [M+2H]2+ at m/z 517.3. The CID 
fragment ions of m/z 517.3 displaced the same 
characteristic –b ion and –y ion series attributed to 
the F*Y[AαC]APELL for both peptide adducts (Fig. 
7A,CID). The shift in mass between the y5 and *y6 
ion series proves that the site of AαC adduction 
occurred at Tyr150 for both peptides (Fig. 7A). CID 
did not provide appreciable fragment ions at the low 
m/z region for either adduct.  The doubly protonated 
ions [M+2H]2+ at m/z 517.3 were subjected to HCD 
to examine for potential fragmentation of the bond 
formed between  the Tyr and AαC.   The extracted 
ion chromatograms were generated at m/z 183.0791 
and m/z 184.0869 (Fig. 7A, HCD). The earlier 
eluting adduct (P9A) at tR 14.5 min displayed a 
prominent fragment ion at m/z 184.0869, an ion 
attributed to protonated AαC (Fig. 7A, HCD at tR 
14.5). The linkage of this adduct may have occurred 
betweeen the C-3 or C-5 atom of the Tyr phenyl ring 
and the exocyclic amino group of AαC. The HCD 
product ion spectrum of the second adduct (P9C) at 
tR 15.8 min showed a mixture of product ions 
assigned as the radical cation of AαC●+ and 
protonated AαC, respectively, at  m/z 183.0789 and 
m/z 184.0868 (Fig. 7A, HCD at tR 15.8).   A Tyr 
linkage may have formed at the C-3 or C-7 atom of 
the heterocyclic ring of AαC, based on studies of 
nucleophilic trapping agents adducting at these sites 
of the nitrenium ion of AαC  (46,48). 
MS characterization an amine-linked AαC 
Tyr adduct— The second set of Tyr-AαC and Tyr-
[13C6]-AαC adducts (A3)  eluted at tR 12.1 min (Fig. 
7B). The protonated ions [M+H]+ were observed, 
respectively at m/z 361.1293 and m/z 367.1475,  a 
mass 2 Da less than the Tyr-AαC and Tyr-[13C6]-
AαC adducts (m/z 363.1449 and m/z  369.1631) 
described  above (Fig. 7B, Table 2). The structure of 
the adduct is proposed to be a quinoneimine  linked 
adduct, which occurs by oxidation of P9A (Fig 7B) 
during proteolytic digestion with the three enzyme 
mixture.  The product ion spectrum of [M+H]+ at 
m/z 361.1293 shows ions at m/z 344.1025,  
315.1239, and 300.1130, which are of losses of, 
respectively, NH3, H2CO2, and NH3 and CO2 (Fig. 
7B, Table 2).   The product ion at m/z 288.1129 is 
proposed to arise following ring-opening of the 
protonated quinoneimine ring (Fig. 7C). The Tyr-
[13C6]-AαC adduct displays the same product ions as 
the unlabeled adduct but shifted by 6 m/z.  
A third peptide adduct formed between AαC 
and Tyr was observed only in the albumin modified 
with N-acetoxy-AαC. The CID-MS/MS spectrum of 
doubly charged protonated precursor ion at m/z 
616.8 at 19.3 min displayed typical –b and –y ion 
pattern attributing to LGMFL*Y[AαC]EY (P6) with 
AαC adduction at Tyr332 (Supplemental Fig. S1, 
upper panel). The [13C6] homologue of this adduct at 
m/z 619.8 displayed the same pattern of 
fragmentation (Supplemental Fig. S1 lower panel).  
AαC-SA adduct formation as a function of 
concentration of N-oxidized AαC metabolites— The 
LQQ*C[SOAαC]PFEDHVK (P3) sulfinamide adduct at 
Cys34 accounted for 73-80% of the total ion counts 
of AαC-peptide adducts, when commercial albumin 
was reacted with a 50-fold molar excess of N-
oxidized AαC metabolites.  In vivo, the exposure to 
AαC occurs at much lower levels than the 
physiological concentration of albumin, and relative 
abundances of adducts formed may be different from 
those adducts formed at elevated exposures to AαC 
in vitro. Therefore, albumin was treated with 
HONH-AαC or N-acetoxy-AαC over  a  millon fold 
range of carcinogen per mol albumin (1 to 10-6) (Fig. 
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8A-B).  We also examined the effect of plasma 
matrix components on the reactivity of albumin with 
N-oxidized AαC metabolites. Representative UPLC-
MS chromatograms of the peptide adducts recovered 
from commercial albumin or albumin in plasma 
modified with 1 molar equivalent of N-acetoxy-AαC 
are shown in Supplemental Fig. 2SA-B.  
The Tyr-peptide adducts of AαC at Tyr140, 
150, 332 residues were only detected when albumin 
was reacted with  ≥ 0.01 mol N-acetoxy-AαC per 
mol albumin. In contrast, adducts were still formed 
at Cys34   with 1 x 10-5 molar ratio of N-acetoxy-
AαC:albumin (Fig. 8A-B), and LQQ*C[SOAαC]P 
FEDHVK sulfinamide was the major adduct. The 
amounts of AαC-peptide adducts formed were ~5-40 
times higher in reactions of albumin conducted with 
N-acetoxy-AαC than those amounts of albumin 
adducts formed with HONH-AαC (Figure 8A-B).  
The level of AαC adduct formation with albumin in 
plasma was several fold lower than adduct levels 
formed with commercial albumin (data not shown).  
Plasma albumin adducts were not detected at Tyr140, 
150, 332 residues at any concentration of N-oxidized 
AαC, and  the sulfinamide LQQ*C[SOAαC]PFEDHVK 
was the predominant adduct. 
AαC-DNA and AαC-albumin adduct 
formation in human hepatocytes— Reactive N-
oxidized intermediates of AαC are formed and 
adduct to DNA in human hepatocytes and albumin 
in human hepatocytes (Fig. 1) (20,33). The basal 
activities of P450 1A1 and 1A2, two major isoforms 
involved in N-oxidation of AαC (16,17), were 
measured in human hepatocytes from three donors  
using ethox-yresorufin and methoxyresorufin as 
substrates (33).  The level of dG-C8-AαC adduct 
formation from the two donors (A and C)  with the 
highest P450 1A1 and 1A2  activities produced  
higher levels of dG-C8-AαC than donor B with low 
enzyme activity (Fig. 9A).  
The mass chromatograms of AαC-albumin 
peptide adducts, following tryptic/chymotryptic 
digestion of albumin recovered from hepatocytes are 
shown in Fig. 9B. The relative ion abundances of the 
peptide adducts are summarized in Fig 9C and 
product ion spectra are presented in Supplemental 
Fig 3S.   The major adduct, based on ion counts, is 
LQQ*C[SOAαC]PFEDHVK sulfinamide, followed by 
LQQ*C[SOAαC]PF, and LQQ*C[AαC]PF. The 
occurrence of the LQQ*C[SOAαC]PFEDHVK as the 
major adduct in hepatocytes  is similar to the 
findings of  commercial albumin and albumin in 
plasma treated with N-oxidized AαC metabolites 
(Fig. 7A, Fig. 8A, Fig. 9B,C). The   LQQ*C[AαC]PF 
sulfenamide and LQQ*C[SOAαC]PF sulfinamide were 
also identified, but occurred at lower ion abundances 
(Fig. 9B,C, Supplemental Fig. 3SA-C). 
LQQ*C[SO2AαC]PF and LQQ*C[SO2AαC]PFEDHVK 
were not detected. 
In the absence of stable, isotopically labelled 
internal standards, quantitative peptide adduct 
measurements and correlations to DNA adduct 
levels of AαC cannot be determined. However, the 
ion counts of the major albumin peptide adduct, 
LQQ*C[SOAαC]PFEDHVK sulfinamide were greatest 
in donor C who also harbored the highest level of 
dG-C8-AαC (Fig. 9A-B,C). Very high levels of AαC 
also were recovered in all of the hepatocytes (Fig.  
9B,C).The occurrence of AαC is attributed to 
hydroysis of S-N linked albumin-AαC  adducts 
during proteolysis and not to unmetabolized AαC 
bound to albumin,  because the isolation procedure 
effectively removed all unbound AαC from albumin 
in the cell culture media (Unpublished observations, 
K. Phatak).  
Oxidative status of albumin-Cys34 and 
albumin-Met329 in human hepatocytes exposed to 
AαC— N-Oxidized metabolites of arylamines 
generate reactive oxygen species (ROS) (49).  We 
sought to determine if AαC had induced oxidative 
stress in hepatocytes by identification of oxidation 
products of Cys34 and Met residues of albumin (50-
52). The oxidized sulfinic LQQ*C[SO2H]PF and 
sulfonic LQQ*C[SO3H]PFEDHVK acids of Cys34 of 
albumin were monitored (29,32), and LQQCPF was 
measured following derivatization of albumin with 
iodoacetamide (IAM) (29).  Elevated levels of the 
protonated [M+H]2+  peptides for 
LQQ*C[SO2H]PFEDHVK at m/z 688.3 and 
LQQ*C[SO3H]PFEDHVK at m/z 696.3 (29) were 
detected in all three sets of hepatocytes treated with 
AαC (Fig 9D). The product ion spectra at m/z 688.3 
and m/z 696.3 displayed typical –b and –y ion series 
type fragment ions (Supplemental Fig.4S A-B) and 
permitted the assigments as the peptide sequences of 
the Cys sulfinic and sulfonic acids (29). The levels 
LQQ*C[SO2H]P FEDHVK and LQQ*C[SO3H]P 
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FEDHVK in AαC/[13C6]AαC-treated hepatocytes 
were, respectively, 6 - 8 and 4 - 6 times higher than 
the levels in untreated controls, and the levels of 
IAM-derivatized LQQ*CPF were decreased by more 
than 10-fold in AαC-treated hepatocytes (Fig. 9B,D). 
Myrimatch search for oxidation sites in albumin also 
identified oxidation at Met329 residue of albumin. 
The product ion spectrum of, trypsin/chymotryptic 
petide DVFLGM[O]F at [M+H]+ at m/z 844.4 
representing Met329 oxidation resulted in typical –b 
and –y type of fragment ions where, -*y2-*y6 and –
*b6 product ions further confirmed oxidation at 
Met329 (Supplemental Fig. 4SC). From targeted 
analysis, the level of  DVFLGM[O]F was ~6 times 
higher in AαC/[13C6]AαC-treated hepatocytes than in 
untreated hepatocytes (Fig. 9B,D).  
DISCUSSION 
Primary human hepatocytes are an ideal ex-
vivo model system for studying metabolism, 
bioactivation and mechanisms of toxicity of 
carcinogens, because cofactors are present at 
physiological concentrations and biotransformation 
pathways may closely simulate those which occur in 
vivo (53). In this study, we investigated the 
metabolic activation of AαC, a rodent liver 
carcinogen, in human hepatocytes, and examined the 
reactivity of its genotoxic N-oxidized metabolites of 
AαC with DNA and albumin. Our goal is to develop 
and implement albumin-based biomarkers of AαC 
and other HAAs  in molecular epidemiological 
studies designed to assess the role of HAAs in 
human cancers (54). The Cys34 residue was the 
major nucleophilic site of albumin to form adducts 
with AαC, followed by Tyr140 and Tyr150, which 
formed adducts at minor levels. Another HAA, PhIP 
(55), also primarily formed adducts at the  Cys34 of 
albumin with considerably lower levels of adducts 
occurring at Tyr140 and Ty150 (56). In contrast, the 
Tyr140 and Tyr150 residues of albumin are the 
preferred site for adduct formation of neurotoxic 
organophosphate compounds (57-59). 
The preliminary characterization AαC-
albumin adducts was performed in vitro. The 
formation of  AαC-albumin adducts was greatly 
enhanced by the in situ generation of N-acetoxy-
AαC, a reactive intermediate of HONH-AαC, which 
undergoes heterolytic cleavage to produce the 
nitrenium ion (48). N-Acetoxy-AαC is a penultimate 
metabolite of AαC that adducts to DNA and proteins 
(17). The N-acetoxy intermediates of HON-AαC, 
and other N-hydroxylated HAAs, such as  2-
hydroxyamino-3-methylimidazo[4,5-f]quinoline and 
2-hydroxyamino-3,8-dimethylimidazo[4,5-
f]quinoxaline are unstable and cannot be isolated 
(60). However, the in situ formation of these N-
acetoxy intermediates in the presence of DNA, by 
reaction of the N-hydroxylated HAAs with acetic 
anhydride, increased the levels of DNA adducts by 
10 to 30 fold (36,61,62). Using a similar reaction 
scheme, we showed that adduct formation of HON-
AαC with albumin was also greatly enhanced by the 
in situ generation of  N-acetoxy-AαC (Fig. 8A-B). 
The Lys, Arg, Cys, and Tyr residues of albumin can 
potentially compete with HONH-AαC and undergo 
acetylation with acetic anhydride and influence the 
formation of different AαC-albumin adducts. 
However, the same AαC-albumin adducts were 
formed by reaction of albumin with a 50 mol excess 
of  HONH-AαC, NO-AαC, or N-acetoxy-AαC 
generated in situ (Table 1).    Moreover, the 
Myrimatch search engine did not detect acetylation 
at Lys, Arg, Cys, or Tyr residues of albumin under 
these reaction conditions (100 mM potassium 
phosphate buffer (pH 7.4, 37 ºC). Under low 
reaction conditions with HONH-AαC (10,000:1; 
albumin:HONH-AαC), the levels of Cys34 adducts 
were 50-fold greater when albumin  was reacted 
with HONH-AαC in the presence of acetic 
anhydride than by reaction of albumin with HONH-
AαC alone; thereby, demonstrating that N-acetoxy-
AαC is efficiently formed in situ and readily reacts 
with nucleophilic sites of albumin to form covalent 
adducts (Fig. 8A-B).  
Human hepatocytes efficiently bioactivated 
AαC to electrophilic N-oxidized metabolites, which 
formed covalent adducts with DNA and albumin 
(Fig. 9). The DNA adduct, dG-C8-AαC, was formed 
at relatively high levels, ranging from 2 – 12 adducts 
per 106 DNA bases, consistent with our previous 
data (20,33).  dG-C8-AαC was also previously 
identified in salivary DNA of smokers (63). The 
Cys34 residue was the sole site of albumin found to 
form adducts with AαC metabolites in hepatocytes: 
both sulfenamide and sulfinamide adducts were 
identified.  However, the ion counts of AαC 
recovered from the albumin digest were 100-fold or 
greater than the ion counts of any of the AαC-Cys 
adducts.  These findings signify that a large 
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proportion of the S-N linked sulfinamide adducts 
LQQ*C[SOAαC]P FEDHVK and LQQ*C[SOAαC]PF,   or 
the sulfenamide adduct LQQ*C[AαC]PF of albumin 
underwent hydrolysis during proteolysis. In the 
absence of stable petide adducts, or isotopically 
labeled LQQ*C[SOAαC]PFEDHVK peptides for 
internal standards, it is difficult to determine the 
relative reactivity of N-oxidized AαC metabolites 
with DNA and albumin in hepatocytes.  
HONH-AαC and NO-AαC undergo redox 
cycling in hepatocytes and produce ROS (Fig. 1) 
(49,64). Previous studies reported that structurally 
related aromatic amines, some of which are  present 
in tobacco smoke (65,66), deplete glutathione levels 
in liver or ex-vivo in hepatocytes of rodents and 
induce oxidative DNA damage (67-69); however, 
the oxidation of albumin was not reported in those 
studies.  In our study, we show that albumin 
scavenges ROS produced by metabolites of AαC in 
human hepatocytes by formation of the oxidized 
Cys34 containing peptides  LQQ*C[SO2H]PFEDHVK, 
LQQ*C[SO3H]PFEDHVK, and the methionine 
oxidation peptide, DVFLGM[O]F. The level of Cys34 
of albumin alkylated with IAM prior to proteolytic 
digestion decreased by more than 90% in 
hepatocytes treated with AαC and provides strong 
evidence that Cys34 of albumin is scavenging ROS 
(Fig. 9C). Together with Cys34, six Met residues of 
albumin display antioxidant activity towards O2●−, 
H2O2, and HOCl (51,52). Met329 was the primary site 
of Met oxidation in albumin from human 
hepatocytes treated with AαC. The oxidation of Met 
residues, particularly Met329, has been observed in 
albumin of hemodialysis patients (52).  
The major adducts of AαC formed with 
albumin were determined in human hepatocytes, by 
employing data-dependent scanning and bottom-up 
proteomics approaches, and the adduction products 
were the same as those adducts formed in vitro with 
commercial albumin reacted with N-oxidized AαC 
intermediates. The dose of AαC (50 µM) employed 
in human hepatocytes is greater than daily human 
exposure to AαC, but comparable to the doses 
employed in studies investigating the genotoxicity of 
AαC (18,19). The amount of AαC arising in 
mainstream smoke is 60 - 250 ng/cigarette (7,8).  
Thus, the intracellular or plasma levels of AαC 
found in humans exposed to this tobacco carcinogen 
are considerably lower than the amount of AαC 
employed in our hepatocyte study. However, dG-C8-
AαC formation occurs in a concentration-dependent 
manner in human hepatocytes treated with AαC over 
a 10,000-fold concentration range (1 nM − 10 μM), 
signifying that the reactive N-oxidation metabolites 
of AαC are formed at physiological exposure levels 
(20). More sensitive mass spectrometric-based 
methods are required for measuring AαC-albumin 
adducts and albumin oxidation products in 
hepatocytes at these lower exposure conditions to 
AαC. 
The Cys34 of albumin accounts for 80% of 
total free thiol content in plasma and considered a 
major antioxidant and scavenger of electrophiles in 
plasma (34). A number of genotoxicants and toxic  
electrophiles  form adducts with the Cys34 of rodent 
or human albumin (23). Many of these adducts have 
been characterized primarily in vitro and several 
adducts have been detected in humans. Albumin 
adducts have been identified with acrylamide (70), 
nitrogen mustard (71), α,β-unsaturated aldehydes 
(26), the neurotoxin brevetoxin B (72), 
acetaminophen (41), benzene (23), and several N-
oxidized HAAs of diverse structures (32,35,56,73). 
In addition, aldehydes produced in tobacco smoke 
are scavenged by Cys34 of albumin in vitro (74). 
Immunochemical techniques have shown carbonyl 
residues are formed with albumin exposed to 
cigarette smoke extract, and the carbonylation of 
albumin, by tobacco smoke, has been detected in 
lung tissue biopsy samples of smokers (75).  
Spectrophotometric assays have shown a decrease in 
the free Cys34 content of albumin following exposure 
to cigarette smoke extracts in vitro (74,76). The 
diminution of free  Cys34 content  may be attributed 
to adducts formed with aldehydes or by oxidation 
with  ROS (26,74,77); however, a correlation 
between the level of adduct formation at Cys34 of 
albumin and cigarette smoking constituents remains 
to established in vivo. Recently, elevated levels of 
Cys34-SO2H of albumin were detected in plasma of  
smokers in a small pilot study (78). AαC, other 
HAAs, and structurally related aromatic amines 
present in tobacco smoke represent a class of 
chemicals in tobacco smoke that may contribute to 
the chemical modification or oxidation of Cys34, and 
the oxidation of Met residues of albumin. 
In summary, AαC, a rodent liver carcinogen 
(12), undergoes bioactivation and forms adducts 
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with DNA and albumin, and induces oxidative stress 
in human hepatocytes. Albumin is a potent 
scavenger of ROS species generated by AαC 
metabolites. AαC, other HAAs, and many aromatic 
amines that arise in mainstream tobacco smoke 
(5,65,66) undergo N-oxidation in humans (54). 
Some of these metabolites form adducts with DNA 
and protein, and also induce oxidative stress, which 
may be contributing factors to liver damage and 
cancer risk in smokers.  The Cys34 adducts of N-
oxidized HAAs and arylamines, or their hydrolysis 
products, and elevated levels of  Cys34-SO2H and 
Cys34-SO3H of albumin may be potential biomarkers 
to assess exposure to these hazardous chemicals in 
tobacco smokers. 
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FIGURE LEGENDS 
 
FIGURE 1.  Bioactivation of AαC, albumin adduct formation and induction of ROS in human 
hepatocytes. AαC undergoes bioactivation by P450 to form HONH-AαC. The HONH-AαC and its N-O 
esters react with albumin to form AαC-Cys34 sulfenamide and sulfinamide adducts, and also react with 
DNA to form dG-C8-AαC. HONH-AαC can undergo further oxidation by P450, transition metals, or by 
oxygen to form NO-AαC and ROS. A redox cycling mechanism catalyzed by NADPH-P450 reductase 
can regenerate HONH-AαC (49,64).  The superoxide anion or other ROS can oxidize S-N linked of Cys-
AαC to form the sulfonamide linkage. The ROS generated by N-oxidized AαC also directly oxidize 
albumin to form the sulfinic and sulfonic acids of Cys34 and Met residues of albumin.   
FIGURE 2. Characterization of AαC and its N-oxidized metabolites. (A) UV spectra of AαC, NO-AαC 
and HONH-AαC were obtained in methanol. Product ion spectra of (B) AαC, (C) NO-AαC, and (D) 
HONH-AαC were acquired by ion trap mass spectrometry. 
FIGURE 3. Mass tag data dependent MS2 scanning of trypsin/chymotrypsin digest of albumin modified 
with 50 mol excess of an equimolar mixture of N-acetoxy-AαC and [13C6] N-acetoxy-AαC. Reconstructed 
ion chromatograms for AαC at m/z 183.1 and 184.1 from digests of albumin modified with N-acetoxy-
AαC/ [13C6] N-acetoxy-AαC (upper panel), or digests of non-modified albumin (lower panel). The 
chromatograms were acquired on ions exhibiting mass difference of m/z 6 (for singly charged ions), m/z 3 
(for doubly charged ions) and m/z 2 (for triply charged ions). The ion intensities were normalized to the 
same scale.  
FIGURE 4. Product ion spectra of AαC adducts of (A)  LQQC[SO2AαC]PFEDHVK (P2) [M+3H]3+ at m/z 
519.6, (B)  LQQC[SOAαC]PFEDHVK (P3) [M+3H]3+ at m/z 514.2, (C) Consecutive reaction monitoring at 
the MS3 scan stage of  LQQC[SOAαC]PFEDHVK (P3)  targeting m/z 679.9 product ion from second 
generation product ion spectrum of m/z 514.2, (D) LQQC[SO2AαC]PF   (P4) [M+2H]2+ at m/z 474.7, (E) 
LQQC[SOAαC]PF  (P7) [M+2H]2+ at m/z 466.7, (F) third generation product ion spectrum of [M+2H]2+ at 
m/z 466.7 > 750.4 > , and (G) LQQC[AαC]PF (P8) [M+2H]2+ at m/z 658.7 of the trypsin/chymotrypsin 
digest of albumin modified with N-acetoxy-AαC and [13C6] N-acetoxy-AαC. *denotes the fragment ions 
with AαC adduction. 
FIGURE 5. AαC-Cys S-dioxide adducts of albumin obtained from pronase E/ prolidase/ leucine amino 
peptidase digest of albumin modified with HONH-AαC and [13C6] HONH-AαC or N-acetoxy-AαC and 
[13C6] N-acetoxy-AαC. Total ion chromatogram (TIC) at the MS2 scan stage of [M+H]+ at m/z 335.0806 
obtained from albumin modified with  (A)  HONH-AαC and (B) N-acetoxy-AαC (lower panel).  The 
product ion spectra of [M+H]+ at m/z 335.0806 of  C[SO2AαC] at (C) at 10.9 min and  (D) at 11.5 min, and 
proposed structures of isomers are shown. (E) Proposed formation of Cysteine-S-yl-dioxide-AαC 
isomeric adducts by reaction of Cys with the nitrenium – carbenium ion resonance forms of HONH-AαC, 
and CID fragmentation mechanism of sulfonium ion at m/z 230.0385 in product ion spectra of isomers 
([M+H]+ at m/z 335.0806).  
FIGURE 6. Product ion spectrum of AαC-Tyr peptide and mono amino acid adduct of albumin modified 
with N-acetoxy-AαC and [13C6] N-acetoxy-AαC.  TIC, HCD and CID product ion spectra of (A) 
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LY[AαC]EIAR (P5) [M+2H]2+  at m/z 473.3, tR 14.1 min, (B) proposed CID fragmentation mechanism of 
LY[AαC]EIAR (P5) adduct [M+2H]2+ at m/z 473.3. (C) TIC and (D) product ion spectrum of  [M+H]+ at 
m/z 363.1449  (A2) at tR 11.8 min, and (E) proposed CID fragmentation mechanism of AαC-Tyr adducts  
[M+H]+  at m/z 363.1452. 
FIGURE 7. Characterization of  isomeric FY[AαC]APELL  peptides and an  AαC-amine-linked Tyr amino 
acid  adduct of albumin modified with N-acetoxy-AαC and [13C6] N-acetoxy-AαC.  TIC, HCD and CID 
product ion spectra of (A) FY[AαC]APELL (P9) [M+2H]2+  at m/z 517.3, tR  14.5 min and 15.8 min (CID 
spectra for both peptides were identical, only the spectrum of peptide at  tR  14.5 min is shown).   (B) TIC 
and CID product ion spectra of AαC-amine-linked Tyr amino acid adduct  [M+H]+ at m/z 361.1299 (A2) 
at tR 12.1 min. (C) Proposed CID fragmentation mechanism of AαC-Tyr adduct [M+H]+ at m/z 361.1299. 
*Denotes the fragment ions with AαC adduction. 
FIGURE 8. Ion counts of AαC-peptide adducts targeting at Cys34 and Tyr140,150 and free AαC recovered 
from trypsin/chymotrypsin digests of (A) albumin modified with 1/10-2 molar equivalent of HONH-AαC 
or N-acetoxy-AαC, 0.3 µg digest/injection  (B) albumin modified with 1/10-4 molar equivalent of HONH-
AαC or N-acetoxy-AαC, 1.0 µg digest/injection. Data are plotted as mean and standard deviation of ion 
counts (N = 3).   
FIGURE 9. (A) Estimates of dG-C8-AαC adduct formation in hepatocytes of Donor A, B and C treated 
with 50 μM of AαC. UPLC-ESI/MS3 chromatograms of dG-C8-AαC from hepatocytes treated with 50 
μM AαC and with DMSO (control). For dG-C8-AαC, ions at m/z 449.1 (MS) > 333.1 (MS2) > 209.2, 
291.4, 316.4 (MS3) (upper level) and for the internal standard, [13C10]-dG-C8-AαC, ions at m/z 459.1 
(MS) > 338.1 (MS2) > 210.2, 295.4, 321.5 (MS3) (lower level) were monitored. (B)  UPLC-ESI/MS2 
chromatograms of AαC-peptide adducts and Cys and Met oxidation products recovered from 
trypsin/chymotrypsin digests of albumin from hepatocytes of Donor A treated with AαC and [13C6] AαC 
(50 µM) and Donor A treated with DMSO (Control). Ion counts of  (C) AαC-peptide adducts and AαC,  
(D)  Cys34 sulfinic acid, Cys34 sulfonic acid, Met329 sulfoxide, and LQQC34PF alkylated with IAM 
obtained from trypsin/chymotrypsin digests of albumin of  hepatocytes of Donor A, B and C treated with 
50 µM  equimolar mixture of AαC and [13C6] AαC for 24 h or treated with DMSO (control). (Values are 
reported as the mean and standard deviation,  N=3). *P < 0.01 using one way ANOVA for Donors A, B 
and C treated with 50 μM of AαC, **P < 0.05 for comparison between Donor A to B and Donor B to C 
using Tukey’s multiple comparison test for DNA adducts. *P < 0.01 and **P < 0.05 AαC treated versus 
control (DMSO treated) (2-tailed t test) for peptide adducts. 
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TABLE 1 AαC-peptide adducts identified using mass-tag data dependent acquisition  
Z – Charge state; tR- Retention time; M.W- Molecular weight; a HONH-AαC/ HONH-[13C6]AαC-albumin modified sample; b N-acetoxy-AαC/ N-
acetoxy-[13C6]-AαC-albumin modified sample; c NO-AαC- modified sample; 3-Enzyme mixture: pronase E,  leucine aminopeptidase,  and 
prolidase.
Peptide 
Unlabeled (13C6labeled) 
Observed precursor ions
(m/z) 
Z 
 
M.W
 
 
tR (min) AαC-peptide adduct Site of modification Enzyme 
P1 481.9 (483.9) 3 1442.6 16.5 32QQ*C[AαC]PFEDHVK
41
 sulfonamide a,b,c Cys34
 
P2 778.9 (781.9) 519.6 (521.6) 
2 
3 1555.7 17.7 
31
LQQ*C[AαC]PFEDHVK
41
 sulfonamide a,b,c Cys34
 
P3 770.9 (773.9) 514.2 (516.3) 
2 
3 1539.7 17.8 
31
LQQ*C[AαC]PFEDHVK
41
 sulfinamide a,b,c Cys34
 
P4 948.4 (954.4) 474.4 (477.4 
1 
2 947.4 17.9 
31LQQ*C[AαC]PF37 sulfonamide a,b,c Cys
34 
 
P5 473.3 (476.3) 2 944.5 19.0 139L*Y[AαC]EIAR144 a,b Tyr140 
P6 616.8 (619.8) 2 1231.5 19.3 327LGMoxiFL*Y[AαC]EY334 a,b Tyr332 
P7 932.4 (938.4) 466.7(469.7) 
1 
2 931.4 20.4 
31LQQ*C[AαC]PF37 sulfinamide a,b,c Cys34 
P8 916.4 (922.4) 458.7 (461.7) 
1 
2 915.4 21.5 
31LQQ*C[AαC]PF37 sulfenamide a,b,c Cys34 
P9(A,B) 517.3 (520.3) 2 1032.5 22.8 149F*Y[AαC]APELL155a,b,c Tyr150 
Trypsin-
chymotrypsin 
Amino 
Acid 
Unlabeled (13C6labeled) 
Observed precursor ions 
(m/z) 
Z 
 
M.W
 
 
tR (min) AαC-amino acid adduct Site of modification Enzyme 
A1 335.0804 (341.0986) 1 335.1 10.9 *Cys[AαC] a,b
 
Cys 
A2 363.1449 (369.1631) 1 363.2 11.8 *Tyr[AαC] a,b
 
Tyr 
A3 361.1293 (367.1475) 1 361.1 12.1 *Tyr[AαC] a,b Tyr 
3-Enzyme 
mixture 
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Table 2 Accurate mass measurements of AαC amino acid adducts formed with Tyr and  Cys 
AαC-amino acid 
adduct 
Precursor 
ion/product ion 
assignment 
Observed 
m/z 
Molecular 
Formula 
Calculated
m/z 
Error 
ppm 
[M+H]+ 363.1449 C20H19N4O3 363.1451 0.5 
[M+H-H3N]+ 346.1184 C20H16N3O3 346.1186 0.5 
[M+H-CH2O2]+ 317.1392 C19H17N4O 317.1396 1.0 
[M+H-CH3NO2]+ 302.1285 C19H16N3O 302.1287 0.7 
[M+H-C2H5NO2]+ 288.1129 C18H14N3O 288.1131 0.7 
[M+H-C9H11NO2]+ 198.0659 C11H8N3O 198.0662 1.0 
AαC-O-Tyr 
 
 [M+H-C9H10NO3]+ 183.0789 C11H9N3 183.0791 1.1 
[M+H]+ 361.1293 C20H17N4O3 361.1295 0.6 
[M+H-H3N]+ 344.1025 C20H14N3O3 344.1029 1.1 
[M+H-CH2O2]+ 315.1239 C19H15N4O 315.1240 0.7 
M+H-CH3NO2]+ 300.1130 C19H14N3O 300.1131 0.7 
[M+H-C2H5NO2]+ 288.1129 C18H14N3O 288.1137 2.8 
[M+H-C9H7NO3]+ 183.0789 C11H9N3 183.0791 1.1 
AαC-N=Tyr 
 
 
[M+H-C9H7NO3]+ 184.0868 C11H10N3 184.0869 0.5 
[M+H]+ 335.0804 C14H15N4O4S 335.0808 1.2 
[M+H-H3N]+ 318.0546 C14H12N3O4S 318.0548 1.2 
[M+H-O2S]+ 271.1193 C14H15N4O2 271.1190 0.4 
[M+H-H3NO2S]+ 254.0928 C14H12N3O2 254.0924 -1.5 
[M+H-C3H12NO3]+ 230.0385 C11H3N3OS 230.0384 0.3 
[M+H-C3H5O4NS]+ 184.0867 C11H10N3 184.0869 1.0 
AαC-HN-SO2-Cys 
 
 
 
 
AαC-SO2-Cys 
 
 
 
 [M+H-C3H6O4NS]
+ 183.0790 C11H9N3 183.0791 0.5 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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Figure 7 
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Figure 8 
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